CMTR1 (Cap Methyltransferase 1)

Unlike nsp14 and nsp16, their functions are not necessarily sequential, but show significant cooperativity. Altogether, our data provide a comprehensive understanding of substrate specificities of human RNA capping methyltransferases, enabling the development of potential future anticancer therapeutics and assessment of antiviral therapeutics' selectivity.

This study demonstrates the effectiveness of combining ML and DL models to identify prognostic gene expression biomarkers in GBM, with DeepSurv providing higher predictive accuracy. The findings offer valuable insights into GBM biology and highlight candidate biomarkers for further validation and therapeutic development.

Our findings establish CMTR1 as an important player in cancer biology, regulating critical aspects of RNA metabolism and ribosome biogenesis. The study highlights CMTR1's potential as a therapeutic target in certain cancer types and provides a foundation for developing novel cancer treatments targeting mRNA cap methylation.

These results indicated that SNORA37/CMTR1/ELAVL1 feedback loop drives gastric cancer progression via facilitating CD44 alternative splicing.

Furthermore, we identify a novel CMTR1 inhibitor, N97911, through in silico screening and biochemical assays, which demonstrates significant anti-tumor activity in vitro . Our findings establish CMTR1 as a key player in cancer biology, regulating critical aspects of RNA metabolism and ribosome biogenesis, and highlight its potential as a therapeutic target across multiple cancer types.

Furthermore, the efficacy of PD1 blockade immunotherapy was prominently enhanced in the presence of CMTR1 KD via increased infiltration of CD8 + T cells into the tumor microenvironment. Overall, it appears that CMTR1 plays a key role in regulating tumor cell proliferation and antitumor immunity.